First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis

C. Bokemeyer, C. Kollmannsberger, C. Meisner, A. Harstrick, J. Beyer, B. Metzner, J. T. Hartmann, H. J. Schmoll, Lawrence Einhorn, L. Kanz, C. Nichols

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

Purpose: To compare first-line high-dose chemotherapy (HD-CT) with autologous blood stem-cell transplantation to standard-dose chemotherapy (SD- CT) in male patients with advanced germ cell tumors (GCTs), a matched-pair analysis was performed within a homogenous group of patients classified as having either Indiana advanced disease or a poor prognosis according to International Germ Cell Cancer Consensus Group (IGCCCG) criteria. Patients and Methods: A multivariate analysis was performed that included 147 consecutive patients who had received sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) therapy (HD-CT) in a German multicenter trial between 1993 and 1997 and 309 patients who had been treated with standard- dose cisplatin, etoposide, and bleomycin (PEB) or VIP chemotherapy (SD-CT) within two randomized trials at Indiana University between 1984 and 1992. Results: Multivariate analysis demonstrated HD-CT to be significantly superior to SD-CT when adjustments were made for prognostic factors (P = .021). Primary tumor site (mediastinal v retroperitoneal/gonadal, P = .035) and presence of visceral metastases (P = .0004) were shown to be significant prognostic factors for overall survival. On the basis of these factors, as well as on tumor marker levels (good, intermediate, or poor, according to IGCCCG criteria), 146 of 147 HD-CT patients were fully matched to an SD-CT patient. Median follow-up was 21 months (range, 0 to 70 months) for the HD-CT patients and 22 months (range, 0 to 90 months) for the SD-CT patients. Two- year progression-free survival (75% v 59%) and overall survival (82% v 71%) were significantly prolonged in HD-CT patients (P = .0056 and P = .0184, respectively). Conclusion: The results indicate that first-line HD-CT in patients with poor-prognosis GCT may result in a significant improvement of progression-free and overall survival as compared with SD-CT. Salvage HD-CT seems not to compensate this survival advantage.

Original languageEnglish (US)
Pages (from-to)3450-3456
Number of pages7
JournalJournal of Clinical Oncology
Volume17
Issue number11
StatePublished - Nov 1999

Fingerprint

Matched-Pair Analysis
Germ Cell and Embryonal Neoplasms
Drug Therapy
Etoposide
Cisplatin
Disease-Free Survival
Survival
Multivariate Analysis
Ifosfamide
Bleomycin
Stem Cell Transplantation
Tumor Biomarkers
Multicenter Studies
Blood Cells

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Bokemeyer, C., Kollmannsberger, C., Meisner, C., Harstrick, A., Beyer, J., Metzner, B., ... Nichols, C. (1999). First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis. Journal of Clinical Oncology, 17(11), 3450-3456.

First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors : A multivariate and matched-pair analysis. / Bokemeyer, C.; Kollmannsberger, C.; Meisner, C.; Harstrick, A.; Beyer, J.; Metzner, B.; Hartmann, J. T.; Schmoll, H. J.; Einhorn, Lawrence; Kanz, L.; Nichols, C.

In: Journal of Clinical Oncology, Vol. 17, No. 11, 11.1999, p. 3450-3456.

Research output: Contribution to journalArticle

Bokemeyer, C, Kollmannsberger, C, Meisner, C, Harstrick, A, Beyer, J, Metzner, B, Hartmann, JT, Schmoll, HJ, Einhorn, L, Kanz, L & Nichols, C 1999, 'First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis', Journal of Clinical Oncology, vol. 17, no. 11, pp. 3450-3456.
Bokemeyer, C. ; Kollmannsberger, C. ; Meisner, C. ; Harstrick, A. ; Beyer, J. ; Metzner, B. ; Hartmann, J. T. ; Schmoll, H. J. ; Einhorn, Lawrence ; Kanz, L. ; Nichols, C. / First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors : A multivariate and matched-pair analysis. In: Journal of Clinical Oncology. 1999 ; Vol. 17, No. 11. pp. 3450-3456.
@article{3e537ab2a93a4e01b0dec79b0a92a6fe,
title = "First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis",
abstract = "Purpose: To compare first-line high-dose chemotherapy (HD-CT) with autologous blood stem-cell transplantation to standard-dose chemotherapy (SD- CT) in male patients with advanced germ cell tumors (GCTs), a matched-pair analysis was performed within a homogenous group of patients classified as having either Indiana advanced disease or a poor prognosis according to International Germ Cell Cancer Consensus Group (IGCCCG) criteria. Patients and Methods: A multivariate analysis was performed that included 147 consecutive patients who had received sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) therapy (HD-CT) in a German multicenter trial between 1993 and 1997 and 309 patients who had been treated with standard- dose cisplatin, etoposide, and bleomycin (PEB) or VIP chemotherapy (SD-CT) within two randomized trials at Indiana University between 1984 and 1992. Results: Multivariate analysis demonstrated HD-CT to be significantly superior to SD-CT when adjustments were made for prognostic factors (P = .021). Primary tumor site (mediastinal v retroperitoneal/gonadal, P = .035) and presence of visceral metastases (P = .0004) were shown to be significant prognostic factors for overall survival. On the basis of these factors, as well as on tumor marker levels (good, intermediate, or poor, according to IGCCCG criteria), 146 of 147 HD-CT patients were fully matched to an SD-CT patient. Median follow-up was 21 months (range, 0 to 70 months) for the HD-CT patients and 22 months (range, 0 to 90 months) for the SD-CT patients. Two- year progression-free survival (75{\%} v 59{\%}) and overall survival (82{\%} v 71{\%}) were significantly prolonged in HD-CT patients (P = .0056 and P = .0184, respectively). Conclusion: The results indicate that first-line HD-CT in patients with poor-prognosis GCT may result in a significant improvement of progression-free and overall survival as compared with SD-CT. Salvage HD-CT seems not to compensate this survival advantage.",
author = "C. Bokemeyer and C. Kollmannsberger and C. Meisner and A. Harstrick and J. Beyer and B. Metzner and Hartmann, {J. T.} and Schmoll, {H. J.} and Lawrence Einhorn and L. Kanz and C. Nichols",
year = "1999",
month = "11",
language = "English (US)",
volume = "17",
pages = "3450--3456",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "11",

}

TY - JOUR

T1 - First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors

T2 - A multivariate and matched-pair analysis

AU - Bokemeyer, C.

AU - Kollmannsberger, C.

AU - Meisner, C.

AU - Harstrick, A.

AU - Beyer, J.

AU - Metzner, B.

AU - Hartmann, J. T.

AU - Schmoll, H. J.

AU - Einhorn, Lawrence

AU - Kanz, L.

AU - Nichols, C.

PY - 1999/11

Y1 - 1999/11

N2 - Purpose: To compare first-line high-dose chemotherapy (HD-CT) with autologous blood stem-cell transplantation to standard-dose chemotherapy (SD- CT) in male patients with advanced germ cell tumors (GCTs), a matched-pair analysis was performed within a homogenous group of patients classified as having either Indiana advanced disease or a poor prognosis according to International Germ Cell Cancer Consensus Group (IGCCCG) criteria. Patients and Methods: A multivariate analysis was performed that included 147 consecutive patients who had received sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) therapy (HD-CT) in a German multicenter trial between 1993 and 1997 and 309 patients who had been treated with standard- dose cisplatin, etoposide, and bleomycin (PEB) or VIP chemotherapy (SD-CT) within two randomized trials at Indiana University between 1984 and 1992. Results: Multivariate analysis demonstrated HD-CT to be significantly superior to SD-CT when adjustments were made for prognostic factors (P = .021). Primary tumor site (mediastinal v retroperitoneal/gonadal, P = .035) and presence of visceral metastases (P = .0004) were shown to be significant prognostic factors for overall survival. On the basis of these factors, as well as on tumor marker levels (good, intermediate, or poor, according to IGCCCG criteria), 146 of 147 HD-CT patients were fully matched to an SD-CT patient. Median follow-up was 21 months (range, 0 to 70 months) for the HD-CT patients and 22 months (range, 0 to 90 months) for the SD-CT patients. Two- year progression-free survival (75% v 59%) and overall survival (82% v 71%) were significantly prolonged in HD-CT patients (P = .0056 and P = .0184, respectively). Conclusion: The results indicate that first-line HD-CT in patients with poor-prognosis GCT may result in a significant improvement of progression-free and overall survival as compared with SD-CT. Salvage HD-CT seems not to compensate this survival advantage.

AB - Purpose: To compare first-line high-dose chemotherapy (HD-CT) with autologous blood stem-cell transplantation to standard-dose chemotherapy (SD- CT) in male patients with advanced germ cell tumors (GCTs), a matched-pair analysis was performed within a homogenous group of patients classified as having either Indiana advanced disease or a poor prognosis according to International Germ Cell Cancer Consensus Group (IGCCCG) criteria. Patients and Methods: A multivariate analysis was performed that included 147 consecutive patients who had received sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) therapy (HD-CT) in a German multicenter trial between 1993 and 1997 and 309 patients who had been treated with standard- dose cisplatin, etoposide, and bleomycin (PEB) or VIP chemotherapy (SD-CT) within two randomized trials at Indiana University between 1984 and 1992. Results: Multivariate analysis demonstrated HD-CT to be significantly superior to SD-CT when adjustments were made for prognostic factors (P = .021). Primary tumor site (mediastinal v retroperitoneal/gonadal, P = .035) and presence of visceral metastases (P = .0004) were shown to be significant prognostic factors for overall survival. On the basis of these factors, as well as on tumor marker levels (good, intermediate, or poor, according to IGCCCG criteria), 146 of 147 HD-CT patients were fully matched to an SD-CT patient. Median follow-up was 21 months (range, 0 to 70 months) for the HD-CT patients and 22 months (range, 0 to 90 months) for the SD-CT patients. Two- year progression-free survival (75% v 59%) and overall survival (82% v 71%) were significantly prolonged in HD-CT patients (P = .0056 and P = .0184, respectively). Conclusion: The results indicate that first-line HD-CT in patients with poor-prognosis GCT may result in a significant improvement of progression-free and overall survival as compared with SD-CT. Salvage HD-CT seems not to compensate this survival advantage.

UR - http://www.scopus.com/inward/record.url?scp=0032703762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032703762&partnerID=8YFLogxK

M3 - Article

C2 - 10550141

AN - SCOPUS:0032703762

VL - 17

SP - 3450

EP - 3456

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 11

ER -